Impact of Antibiotic Resistance Genes in Gut Microbiome of Patients With Cirrhosis
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved..
BACKGROUND AND AIMS: Cirrhosis is associated with changes in intestinal microbiota that can lead to hepatic encephalopathy (HE) and infections, especially with antibiotic-resistant organisms. However, the impact of gut microbial antibiotic resistance gene (ARG) burden on clinical outcomes is unclear. The aims of the study were to determine the impact of ARGs in cirrhosis-related gut metagenome on outcomes and disease progression, study the effect of rifaximin on ARG burden, and compare ARGs in cirrhosis with chronic kidney disease (CKD) and diabetes.
METHODS: In outpatients with cirrhosis who underwent metagenomics, we evaluated change in ARG abundances with progression and their multivariable impact on 90-day hospitalizations and deaths over 1 year. We also studied ARGs pre- and 8 weeks post-rifaximin in patients with compensated cirrhosis in an open-label trial. Finally, ARGs from CKD and diabetes studies were compared with cirrhosis on machine learning.
RESULTS: A total of 163 patients with cirrhosis (43 compensated, 20 ascites-only, 30 HE-only, 70 both) and 40 controls were included. ARG abundances were higher in cirrhosis versus controls and worsened with advancing cirrhosis severity; 44 patients were hospitalized and 14 died. ARG abundances were associated with hospitalizations and mortality while controlling for cirrhosis complications, medications, and demographics. Rifaximin trial: ARG abundance patterns were minimally affected in 19 patients post-rifaximin. CKD/diabetes comparison: ARG abundance patterns in cirrhosis are distinguishable on machine learning and include more gram-positive ARGs.
CONCLUSIONS: Cirrhosis is associated with high gut microbial ARG gene burden compared with controls, which worsens with disease progression and may be different from CKD and diabetes. ARGs are not affected by rifaximin and are associated with hospitalizations and death.
| Errataetall: |
CommentIn: Gastroenterology. 2021 Aug;161(2):413-415. - PMID 34048780 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:161 |
|---|---|
| Enthalten in: |
Gastroenterology - 161(2021), 2 vom: 08. Aug., Seite 508-521.e7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shamsaddini, Amirhossein [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 18.01.2022 Date Revised 02.08.2022 published: Print-Electronic CommentIn: Gastroenterology. 2021 Aug;161(2):413-415. - PMID 34048780 Citation Status MEDLINE |
|---|
| doi: |
10.1053/j.gastro.2021.04.013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324122160 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324122160 | ||
| 003 | DE-627 | ||
| 005 | 20231225185638.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1053/j.gastro.2021.04.013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1080.xml |
| 035 | |a (DE-627)NLM324122160 | ||
| 035 | |a (NLM)33857456 | ||
| 035 | |a (PII)S0016-5085(21)00634-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shamsaddini, Amirhossein |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of Antibiotic Resistance Genes in Gut Microbiome of Patients With Cirrhosis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.01.2022 | ||
| 500 | |a Date Revised 02.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Gastroenterology. 2021 Aug;161(2):413-415. - PMID 34048780 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND AND AIMS: Cirrhosis is associated with changes in intestinal microbiota that can lead to hepatic encephalopathy (HE) and infections, especially with antibiotic-resistant organisms. However, the impact of gut microbial antibiotic resistance gene (ARG) burden on clinical outcomes is unclear. The aims of the study were to determine the impact of ARGs in cirrhosis-related gut metagenome on outcomes and disease progression, study the effect of rifaximin on ARG burden, and compare ARGs in cirrhosis with chronic kidney disease (CKD) and diabetes | ||
| 520 | |a METHODS: In outpatients with cirrhosis who underwent metagenomics, we evaluated change in ARG abundances with progression and their multivariable impact on 90-day hospitalizations and deaths over 1 year. We also studied ARGs pre- and 8 weeks post-rifaximin in patients with compensated cirrhosis in an open-label trial. Finally, ARGs from CKD and diabetes studies were compared with cirrhosis on machine learning | ||
| 520 | |a RESULTS: A total of 163 patients with cirrhosis (43 compensated, 20 ascites-only, 30 HE-only, 70 both) and 40 controls were included. ARG abundances were higher in cirrhosis versus controls and worsened with advancing cirrhosis severity; 44 patients were hospitalized and 14 died. ARG abundances were associated with hospitalizations and mortality while controlling for cirrhosis complications, medications, and demographics. Rifaximin trial: ARG abundance patterns were minimally affected in 19 patients post-rifaximin. CKD/diabetes comparison: ARG abundance patterns in cirrhosis are distinguishable on machine learning and include more gram-positive ARGs | ||
| 520 | |a CONCLUSIONS: Cirrhosis is associated with high gut microbial ARG gene burden compared with controls, which worsens with disease progression and may be different from CKD and diabetes. ARGs are not affected by rifaximin and are associated with hospitalizations and death | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a Ascites | |
| 650 | 4 | |a Hepatic Encephalopathy | |
| 650 | 4 | |a Infections | |
| 650 | 4 | |a Machine Learning | |
| 650 | 4 | |a Rifaximin | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Rifaximin |2 NLM | |
| 650 | 7 | |a L36O5T016N |2 NLM | |
| 700 | 1 | |a Gillevet, Patrick M |e verfasserin |4 aut | |
| 700 | 1 | |a Acharya, Chathur |e verfasserin |4 aut | |
| 700 | 1 | |a Fagan, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Gavis, Edith |e verfasserin |4 aut | |
| 700 | 1 | |a Sikaroodi, Masoumeh |e verfasserin |4 aut | |
| 700 | 1 | |a McGeorge, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Khoruts, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Albhaisi, Somaya |e verfasserin |4 aut | |
| 700 | 1 | |a Fuchs, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Sterling, Richard K |e verfasserin |4 aut | |
| 700 | 1 | |a Bajaj, Jasmohan S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastroenterology |d 1945 |g 161(2021), 2 vom: 08. Aug., Seite 508-521.e7 |w (DE-627)NLM00001706X |x 1528-0012 |7 nnns |
| 773 | 1 | 8 | |g volume:161 |g year:2021 |g number:2 |g day:08 |g month:08 |g pages:508-521.e7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1053/j.gastro.2021.04.013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 161 |j 2021 |e 2 |b 08 |c 08 |h 508-521.e7 | ||